Hologic (HOLX) Tops Q2 EPS by 4c, Beat on Revenues; Raises FY17 Guidance

Hologic (NASDAQ: HOLX) reported Q2 EPS of $0.50, $0.04 better than the analyst estimate of $0.46. Revenue for the quarter came in at $715.4 million versus the consensus estimate of $685.36 million.

GUIDANCE:

Hologic sees FY2017 EPS of $1.98-$2.02, versus the consensus of $1.98. Hologic sees FY2017 revenue of $3.05-3.08 billion, versus the consensus of $3.06 billion.

For earnings history and earnings-related data on Hologic (HOLX) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO